NCT06328673 - A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

DM919

Anti-MICA/MICB monoclonal antibody

DRUG

Pembrolizumab

Anti-PD-1 monoclonal antibody

Trial Locations (2)

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS), Beijing